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D1 and D2 dopamine receptors are expressed in dis-
joint subsets of striatal projection neurons, the direct
and indirect pathways, respectively. This differential
distribution of receptors forms the basis for explana-
tions of many aspects of basal ganglia function and
dysfunction, but it seems incompatible with some
other important properties of striatal neurons. In this
issue of Neuron, Wang et al. discover the mechanism
of D2 sensitivity of long term depression at synapses
on the striatal projection neuron. They show that D2
dependence of LTD does not depend on dopamine
receptors of on the projection cell but is mediated by
dopamine-induced changes in releaseof acetylcholine
by interneurons that contact projection cells of both
types.
The differential roles of D1 and D2 dopamine receptors
have been a recurring theme in the study of the basal
ganglia neurophysiology and behavioral pharmacology.
At the core of most models of the pathophysiology of
Parkinson’s disease lies the idea that D1 and D2 recep-
tors differentially affect the two groups of striatal princi-
pal neurons, the cells of the direct and indirect path-
ways. One premise of these models, that D1 receptors
are expressed by approximately one half of all striatal
projection neurons and D2 receptors by the other, has
been established by studies of RNA content and protein
expression (Gerfen, 1992; Surmeier et al., 1996). This
general arrangement is shown in Figure 1. Cells of both
types are GABAergic and have very similar appearance
and firing patterns. But the ones that express the D1
receptor also express substance P as a cotransmitter,
and their axons innervate both segments of the globus
pallidus and substantia nigra. These cells, the direct
pathway cells, make monosynaptic connections to the
basal ganglia output neurons in the internal globus
pallidus segment and substantia nigra, pars reticulata.
The D2-expressing striatal projection neurons contain
dynorphin and enkephalin, and their axons project only
as far as the external segment of the globus pallidus,
where they can contact no basal ganglia output cells.
The differential control of these two pathways by dopa-
mine forms the basis for the explanation of a large body
of empirical data on these structures and their relation-
ship to behavior.
On the other hand, there has long been another thread
of research insisting that D1 and D2 receptors are colo-
calized on spiny cells. Studies of dopaminergic modula-
tion of ion channels, firing properties, and synaptic trans-
mission have shown that individual spiny neurons
respond to both D1 and D2 agonists (e.g., Aizman et al.
[2000]; Surmeier et al. [1993]). It has been difficult to rec-
oncile these two lines of thought, each of which is sup-
ported by a large body of experimental data. One of the
clearest phenomena that appears to require coexistence
of dopamine receptors on spiny neurons is long-term de-
pression (LTD) of glutamatergic afferent synapses on the
spiny neuron. It has been shown that high-frequencystimulation of glutamatergic afferents will evoke LTD in
effectively all striatal projection neurons. The tricky part
is that LTD has been shown to require activation of D2
receptors. How can LTD depend on D2 receptor activa-
tion in spiny projection neurons that don’t express the
D2 receptor? Similar results abound. NMDA receptor-
dependent LTP is also seen in most or all spiny projec-
tion neurons but is blocked by antagonists of D1 recep-
tors (Kerr and Wickens, 2001; Centonze et al., 2003). D1
and D2 receptor agonists alter excitability in all spiny
neurons (Onn et al., 2003; Ding and Perkel, 2002), and
there are many studies showing nonadditive effects of
D1 and D2 receptor on biochemical and behavioral mea-
sures (e.g., Keefe and Gerfen [1995]). Faced with these
results, some have insisted that the results showing dif-
ferential distribution of D1 and D2 receptors in the stria-
tum must simply be wrong. One source of doubt about
these experiments concerns identification of neurons.
The arguments about cell identity have been indirect, be-
ing based on the assumption of equal sampling of direct
and indirect pathway spiny neurons. In a more perfect
world, we would determine the identity of every single
cell at the time of the experiment and show for sure
whether direct pathway neurons could respond to D2
receptor agonists.
Showing that spiny projection cells lacking the D2 re-
ceptor respond to D2 agonists within the circuitry of the
striatum isn’t all that startling. Spiny cells predominate in
the striatum, but there are plenty of other cell types. The
distribution of dopamine receptors has not been deter-
mined for all the interneurons, but at least one kind of in-
terneuron has been shown to have both receptor types.
The cholinergic interneuron, representing only about 1/
100 of the cells in the striatum, has long been known
to be responsive to dopamine. Investigators studying
dopamine regulation of acetylcholine turnover in the
1970’s concluded that the influence of dopamine in the
striatum was primarily exerted on the cholinergic in-
terneuron, which relayed its effects to the spiny cells.
This line of work, refined over 30 years, shows that ace-
tylcholine release in the striatum is tightly regulated by
dopamine via both D1 and D2 receptor types (DeBoer
and Abercrombie, 1996). But the idea of primary media-
tion of dopamine effects by acetylcholine lost its pur-
chase when dopamine receptors were discovered on
the spiny cells. The most parsimonious explanation
was that dopaminergic control of spiny cells was direct.
In this issue of Neuron, Wang and colleagues (2006)
look directly at the D2-receptor sensitivity of LTD in
spiny neurons. They use BAC transgenic mice with fluo-
rescent reporters driven by the D1- or D2-receptor pro-
moters to identify cells at the time of the experiment and
show that D2-receptor-dependent LTD occurs as read-
ily in both the direct and indirect pathway spiny cells.
In a sequence of pharmacological experiments they re-
veal the participation of at least five intervening steps
between the D2 receptor and LTD of glutamatergic syn-
apses on the spiny neuron. The cholinergic neurons
play the key role of intermediate between dopamine
and the spiny neuron, and the spiny neuron D2 receptor
appears nowhere in the explanation. D2 receptors on
the cholinergic cell act to inhibit the release of acetyl-
choline, which reduces the m1-mediated inhibitory
modulation of L-type calcium channels, resulting in
Keeping Time without a Clock
The accepted dogma in circadian biology is that the
transcription factor CLOCK lies at the heart of the mo-
lecular clock that drives behavioral and molecular
rhythms. In this issue of Neuron, the generation of
CLOCK-deficient mice with only subtle clock defects
by DeBruyne et al. shakes up this view of the mamma-
lian clock.
Circadian biologists like to boast that theirs is the best-
understood behavior at the molecular level and that the
circadian clock underlies large amounts of our physiol-
ogy: the master clock in the suprachiasmatic nucleus
(SCN) of the hypothalamus drives daily rhythms in sleep/
wake cycles and body temperature, while the clocks
of peripheral tissues such as the liver drive rhythms
in detoxification and liver regeneration. Furthermore,
desynchronization of the internal body clock from the
environment increases the risk of developing various
types of cancer. The current model places two tran-
scription factors—CLOCK and BMAL1—at the core of
this SCN clock; together, they activate the transcription
of the mCry1–2 and mPer1–3 genes. The resulting CRY/
PER protein dimers translocate into the nucleus and
repress CLOCK/BMAL1 activity, leading to w24 hr
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of cannabanoids from the postsynaptic spiny neuron,
which then acts presynaptically to reduce the release
of glutamate. The mechanism as they show it explains
a number of well-known features of striatal LTD, includ-
ing its dependence on L-type calcium channels and me-
tabotropic glutamate receptors. It is complicated, how-
ever. It is so complicated that if it had been proposed in
the absence of so clear an experimental demonstration
of its truth, it would probably have been rejected as un-
parsimonious. One lesson if this work is that parsimony
is often not a reliable basis of judgment. We have clearly
been using Occam’s Razor incorrectly, and maybe it
would be best if we just left it alone for a while.
One implication of these findings concerns the spa-
tial range of dopamine’s effects. When dopamine was
thought to act directly on spiny neurons, one could
imagine its effects being localized to limited parts of
the spiny cell, or even particular synapses. In the au-
thors’ diagram in Figure 7, the critical parts of the signal-
ing pathway controlling release of endocannabanoids,
including the m1 receptor, are shown as contained
within a dendritic spine. This localization of everything
in each spine is not meant to be taken too literally. Cho-
linergic interneurons are few and their dendritic and ax-
onal arborizations are widespread. The effects of dopa-
mine relayed through cholinergic cells probably occur
on a spatial scale larger than a single synapse, or even
a single spiny cell. Synaptic specificity for LTD must
be mediated by the glutamatergic side of the mecha-
nism, either in the local activation of voltage-gated cal-
cium channels in the spine (e.g., Carter and Sabatini
[2004]), in the mGluR activation that can trigger release
of calcium from intracellular stores, or both.
These findings forecast a comeback for the choliner-
gic cell as an intermediary between dopaminergic inputs
Figure 1. Relationship of Spiny Neurons, Cholinergic Interneurons,
Glutamatergic Afferents, and Dopamine Axons in the Striatumand spiny cells, especially in matters involving the inter-
action of D1 and D2 receptors.
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